| 摘要 |
The invention disclosed is a process for determining the cytoprotective activity of plasma that prevents the destruction of endothelial cells and forestalls the development of a number of diseases such as atherosclerosis, preeclampsia, edema, nephrotic syndrome, and stroke. The present invention includes a method of diagnosing a patient's proclivity to develop a disease having a correlation to a reduction in the concentration of pI 5.6 albumin in the plasma by determinin g a value indicative of the concentration of the pI. 5.6 albumin that is not bound to VLDL ("non-VLDL-bound pI 5.6 albumin") in the patient's blood serum. The preferre d embodiment of the process utilizes in vitro methods to obtain an indicator o f the non-VLDL-bound pI. 5.6 albumin instead of directly measuring the concentrati on of the non-VLDL-bound pI 5.6 albumin. |
